Detail akcie Harrow Health Rg online

Business Summary: Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Harrow Inc revenues increased 34% to $111.6M. Net loss decreased 36% to $12.8M. Revenues reflect Branded segment increase of 70% to $70.1M. Lower net loss reflects FV Adjustments of Financial Investments decrease from $3.2M (expense) to $0K, Stock-based Compensation in SGA decrease of 34% to $5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.56 to -$0.36.